Thus, we carried out an analysis of EGFR and KRAS mutational status, EGFR copy number and the expression of EGFR, HER2, pCMET, pAKT, PTEN, pSTAT3, pSTAT5, pERK, HIF-1α, E-cadherin and vimentin, in resected NSCLC patients to assess their potential combined prognostic significance with respect to overall survival. This evidence concerns the gene KRAS and non-small cell lung carcinoma.